Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study

被引：2
|
作者：
Lee, C. [1 ]
Tang, Y. [1 ]
Schroeder, C. [1 ]
Zhang, J. [1 ]
Nguyen-Cleary, T. [1 ]
Mullin, S. [1 ]
Ma, M. [1 ]
Lyon, N. [1 ]
Grundy, J. [1 ]
机构：
[1] Arena Pharmaceut Inc, San Diego, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.415
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P291
引用
收藏
页码：S321 / S322
页数：4
相关论文
共 50 条
  • [41] Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects
    Chen, Qian
    Qian, Hong-jie
    Wang, Wei
    Zhang, Meng-qi
    Lu, Dong-ying
    Lu, Chuan
    Jin, Jie-mei
    Hu, Chao-ying
    Liu, Gang-yi
    Jia, Jing-ying
    Zheng, Hong-chao
    Li, Xue-ning
    Yu, Chen
    Wang, Yi-ping
    Liu, Yun
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 (01) : 120 - 125
  • [42] An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment
    Nakamaru, Yoshinobu
    Kakubari, Masae
    Yoshida, Kaori
    Akimoto, Makoto
    Kondo, Kazuoki
    CLINICAL THERAPEUTICS, 2020, 42 (09) : 1699 - 1714
  • [43] A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
    Ou, Ying C.
    Preston, Richard A.
    Marbury, Thomas C.
    Tang, Zhiyu
    Novotny, William
    Tawashi, Manal
    Li, Ta-Kai
    Sahasranaman, Srikumar
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1355 - 1363
  • [44] Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study
    Dahlke, Marion
    Halabi, Atef
    Canadi, Jasna
    Tsubouchi, Chiaki
    Machineni, Surendra
    Pang, Yinuo
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (04): : 474 - 483
  • [45] A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
    Gao, Ling
    Yamamiya, Ikuo
    Pinti, Mark
    Rondon, Juan Carlos
    Marbury, Thomas
    Tomlinson, Gareth
    Makris, Lukas
    Hangai, Nanae
    Wacheck, Volker
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (09): : 1713 - 1724
  • [46] Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment
    Kuipers, Mirjam
    Smulders, Ronald
    Krauwinkel, Walter
    Hoon, Timothy
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 102 (04) : 405 - 412
  • [47] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Magda S. C. Fontes
    Jasper Dingemanse
    Atef Halabi
    Monika Tomaszewska-Kiecana
    Patricia N. Sidharta
    Scientific Reports, 12
  • [48] Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
    Fontes, Magda S. C.
    Dingemanse, Jasper
    Halabi, Atef
    Tomaszewska-Kiecana, Monika
    Sidharta, Patricia N.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [49] An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function
    Tomkinson, H. K.
    Weil, A.
    Engelhardt, E.
    Schmid, K.
    Oliver, S.
    Morris, T.
    Swaisland, H.
    Taboada, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 132 - 132
  • [50] A Phase 1 Single-dose Open-label Pharmacokinetic (PK) Study of Abiraterone Acetate (AA) in Male Subjects With Mild or Moderate Hepatic Impairment
    Marbury, T.
    Stonerock, R.
    Acharya, M.
    Gonzalez, M.
    Jiao, J.
    Breeding, J.
    Haqq, C.
    Molina, A.
    Tran, N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S501 - S501
12345